President Joe Biden’s Inflation Reduction Act allows Medicare to negotiate costly drug prices with pharmaceutical companies.
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
Democratic lawmakers filed an amicus brief in an appeals case as the pharmaceutical industry fights a “pile-up” of losses in ...
Jared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.
Results from Medicare’s first year of negotiation with other price benchmarks shed light on the competitive dynamics and ...
WASHINGTON — Sen. Bill Cassidy (La.), a key Republican senator with seats on the chamber’s health and finance committees, ...
When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those ...
1d
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...
The ability to afford needed medicines is about dignity, hope and fairness. Those words have been at the center of our work ...
The Inflation Reduction Act raids an estimated $260 billion in reduced Medicare drug spending to pay for unrelated spending.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback